首页 > 市场调查报告书 > 製药

生物标记

市场调查报告书

商品编码

1410027

数位生物标记市场 – 2023 年至 2028 年预测

Digital Biomarkers Market - Forecasts from 2023 to 2028

出版日期: 2023年12月13日 | 出版商:

Knowledge Sourcing Intelligence | 英文 147 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

数位生物标记市场预计在预测期内将以 9.22% 的复合年增长率成长。

穿戴式装置、行动健康应用程式和远端患者监护解决方案的出现放大了数位生物标记市场的成长。这些技术提供的对生命征象、活动量、睡眠模式和其他健康相关因素的连续、非侵入性监测会产生大量资料，可以对这些数据进行分析以提供有用的见解。随着医疗保健产业拥抱数位转型，数位生物标记的市场规模预计将大幅扩大。先进分析、人工智慧和机器学习演算法的应用将增加数位生物标记的价值和可用性。这为疾病预防、个体化治疗和改善患者治疗结果带来了新的机会。

市场驱动因素：

穿戴式装置和行动健康应用程式的采用率增加：

随着穿戴式装置和行动健康应用程式的日益普及，数位生物标记市场正在向前发展。使用者可以利用这些技术测量生命体征，收集各种健康指标的资料，并以易于使用的方式了解自己的健康状况。随着穿戴式装置和行动应用程式的普及，现在可以以更个人化和精确的方式创建和使用数位生物标记。

远端患者监护方案的需求量很大：

由于对远端患者监护方案的需求不断增加，数位生物标记市场正在显着扩大。远端患者监护可让医疗保健专业人员远端监控患者健康状况、收集即时资料并识别潜在问题。这项需求是由提供高效且具成本效益的医疗保健的需求所驱动的，特别是对于慢性病患者和需要持续监测的患者。

医疗保健组织和技术公司之间的合作和联盟：

由于科技公司和医疗机构之间的大量合作，数位生物标记市场预计将出现积极成长。这些将临床专业知识与技术进步相结合的合作使得数位生物标记在医疗保健环境中的成功创新解决方案和应用成为可能。

扩展数位基础设施和连接：

扩大数位生物标记市场需要扩大数位基础设施和连接。随着互联网的普及、通讯的进步以及 5G 网路的引入，数位生物标记现在可以无缝整合到医疗保健系统中。所有这些因素都在增加资料收集、储存和分析的机会。

预计北美将占据主要市场占有率。

由于该地区先进的医疗基础设施和对数位医疗技术的大量投资，预计北美将占据重要的市场占有率。此外，该地区大型製药企业的存在促进了数位生物标记物开发的合作和创新。此外，数位生物标记市场的成长受到有利的政府倡议和政策的推动。最后，北美数位生物标记市场占有率得到了穿戴式装置、行动健康应用和远端患者监护解决方案的快速普及的支持。

数位生物标记市场的主要企业

Biofourmis：一个名为 Biofourmis 的综合数位治疗平台，利用穿戴式科技和人工智慧来收集和分析患者产生的健康资料。我们为慢性病管理和急性后护理提供个人化见解、预测分析和远端监控等选项。
Evidation Health：一家透过分析数位设备的真实资料来创建和检验数位生物标记的公司。该公司使用的技术收集和分析来自各种来源的资料，从而能够为多种疾病创建和评估新的生物标记。
Empatica： Empatica 的智慧型手錶和腕带是测量各种生理特征的可穿戴设备的范例。从设备收集的心率、皮肤电活动和活动水平资料可以找到压力和癫痫等疾病的数位生物标记。

主要进展：

2023 年 3 月，中外製药株式会社与技术支援护理服务领域的全球领导者 Biofourmis 签订了一项持续协议，将开发数位技术以客观评估子宫内膜异位症患者的疼痛。一项关于研究和实用化的新合作协议被宣布。 10%的育龄女性患有子宫内膜异位症，其中70%患有慢性骨盆腔不适，影响生活品质。 2023 年 1 月，杜克大学 BIG IDEAs 实验室与 Evidation 建立了合作伙伴关係，透过建立在日常生活中提供更好的健康分析的分析结构来增加数位健康研究的多样性和包容性。

介绍
北美洲
- 美国
- 加拿大
- 墨西哥
南美洲
- 巴西
- 阿根廷
- 其他的
欧洲
- 英国
- 德国
- 法国
- 义大利
- 西班牙
- 其他的
中东/非洲
- 沙乌地阿拉伯
- 阿拉伯聯合大公国
- 其他的
亚太地区
- 日本
- 中国
- 印度
- 韩国
- 印尼
- 台湾
- 其他的

第九章竞争环境及分析

主要企业及策略分析
市场占有率分析
合併、收购、协议和伙伴关係

第十章公司简介

Biofourmiss
SonderMind
Evidation Health Inc.
ResMed Inc.
Eerily Life Science LLC
Empatica Inc.
Koneska Health

简介目录

Product Code: KSI061615676

The digital biomarkers market is estimated to grow at a CAGR of 9.22% during the forecast period.

The digital biomarkers market growth is expanding as wearable devices, mobile health applications, and solutions for remote patient monitoring emerge. Continuous, non-invasive monitoring of vital signs, activity levels, sleep patterns, and other health-related factors is provided by these technologies, which generate a wealth of data that can be analyzed to provide useful insights. As the healthcare industry embraces digital transformation, it is anticipated that the digital biomarkers market size will expand significantly. Digital biomarkers' value and usability will rise as a result of the application of advanced analytics, AI, and machine learning algorithms. This will open up new opportunities for disease prevention, individualized treatment, and improved patient outcomes.

Market Drivers:

Increasing Adoption of Wearable Devices and Mobile Health Applications:

The digital biomarkers market is moving forward as wearable devices and mobile health apps are becoming more and more popular. Users can use these technologies to measure vital signs, collect data on a variety of health metrics, and keep track of their health in an easy-to-use manner. Digital biomarkers can now be created and used in a more personalized and precise manner thanks to the growing use of wearables and mobile applications.

Remote Patient Monitoring Solutions are in High Demand:

The digital biomarkers market is experiencing significant expansion as a result of the rising demand for remote patient monitoring solutions. Healthcare professionals can remotely monitor their patient's health status, collect real-time data, and identify potential issues with remote patient monitoring. This demand is being driven by the need for healthcare delivery that is both efficient and cost-effective, particularly for patients who have chronic conditions or who require continuous monitoring.

Collaborations and alliances between healthcare organizations and technology firms:

The digital biomarkers market is expected to show positive growth as a result of numerous collaborations between technology companies and healthcare organizations. Innovative solutions and the successful application of digital biomarkers in healthcare settings are made possible by these collaborations, which combine clinical expertise with technological advancements.

Expansion of Digital Infrastructure and Connectivity:

The expansion of digital infrastructure and connectivity is necessary for the digital biomarkers market to expand. Digital biomarkers can now be seamlessly integrated into healthcare systems owing to the widespread adoption of the internet, advancements in telecommunications, and the introduction of 5G networks. All of these factors have increased access to data collection, storage, and analysis.

North America is anticipated to account for a significant market share.

The North America will hold a considerable market share which is attributable to the region's sophisticated healthcare infrastructure and significant investments in digital health technology. Likewise, the presence of significant pharmaceutical conglomerates and technological giants in the region encourages collaboration and innovation in the development of digital biomarkers. Furthermore, digital biomarkers market growth is fuelled by favorable government initiatives and policies. Lastly, North America's dominance in the digital biomarkers market share is aided by the region's rapid adoption of wearable devices, mobile health applications, and remote patient monitoring solutions.

Key Players in the Digital Biomarkers Market:

Biofourmis: Utilizing wearable technology and artificial intelligence, the comprehensive digital therapeutics platform known as Biofourmis collects and analyses health data generated by patients. For managing chronic conditions and providing post-acute care, some of their options include personalized insights, predictive analytics, and remote monitoring.
Evidation Health: Evidation Health is a company that works on digital biomarker creation and validation by analyzing real-world data from digital devices. The technology they use collects and analyses data from a variety of sources, making it possible to create and evaluate new biomarkers for a wide range of diseases.
Empatica: Smartwatches and wristbands made by Empatica are examples of wearable devices that measure a variety of physiological characteristics. They can find digital biomarkers for conditions like stress and epilepsy thanks to the data they collect from their devices about heart rate, electrodermal activity, and activity levels.

Key Developments:

In March 2023, A new cooperation agreement was announced between Chugai Pharmaceutical Co., Ltd. and Biofourmis, a global leader in technology-enabled care delivery, for ongoing research and the practical application of digital technologies to objectively assess endometriosis patients' pain. 10% of all women of reproductive age are affected by endometriosis, and 70% of those women suffer from chronic pelvic discomfort, affecting their quality of life.
In January 2023, A partnership between the Duke University BIG IDEAs Lab and Evidation was formed to increase diversity and inclusion in digital health research by building an analytic structure that would provide better health analysis in everyday life.

Segmentation

BY TYPE

Mobile Health Apps
Wearable Devices
Others

BY THERAPEUTIC AREA

Cardiovascular Disorders
Neurological Disorders
Respiratory Disorders
Metabolic Disorders
Others

BY END-USER

Pharmaceutical Companies
Healthcare Providers
Research Organizations
Others

BY GEOGRAPHY

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Italy
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Taiwan
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Research Process

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Market Opportunities
4.4. Porter's Five Force Analysis
- 4.4.1. Bargaining Power of Suppliers
- 4.4.2. Bargaining Power of Buyers
- 4.4.3. Threat of New Entrants
- 4.4.4. Threat of Substitutes
- 4.4.5. Competitive Rivalry in the Industry
4.5. Industry Value Chain Analysis

5. DIGITAL BIOMARKERS MARKET BY TYPE

5.1. Introduction
5.2. Mobile Health Apps
5.3. Wearable Devices
5.4. Others

6. DIGITAL BIOMARKERS MARKET BY THERAPEUTIC AREA

6.1. Introduction
6.2. Cardiovascular Disorder
6.3. Neurological Disorder
6.4. Respiratory Disorder
6.5. Metabolic Disorder
6.6. Other

7. DIGITAL BIOMARKERS MARKET BY END-USER

7.1. Introduction
7.2. Pharmaceutical Companies
7.3. Healthcare Providers
7.4. Research Organizations
7.5. Others

8. DIGITAL BIOMARKERS MARKET BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. United States
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. United Kingdom
- 8.4.2. Germany
- 8.4.3. France
- 8.4.4. Italy
- 8.4.5. Spain
- 8.4.6. Others
8.5. Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Others
8.6. Asia Pacific
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Taiwan
- 8.6.7. Others